Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.
Lyell Immunopharma has raised $100.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2025.
Lyell Immunopharma's investors include ARCH Venture Partners, Bill & Melinda Gates Foundation, Mubadala, Arrive, Sahsen Ventures.
Lyell Immunopharma is headquartered in South San Francisco, United States.
Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.
Lyell Immunopharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Lyell Immunopharma — Funding & Investors." VCBacked, July 25, 2025, https://www.vcbacked.co/company/lyell-immunopharma. Accessed July 19, 2026.
VCBacked. (2025). Lyell Immunopharma — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/lyell-immunopharma
{{cite web |title=Lyell Immunopharma — Funding & Investors |url=https://www.vcbacked.co/company/lyell-immunopharma |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated